4,4'-bis-(2-phthalimido-ethyl)-[2,2']bithiazolyl

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异吲哚及其衍生物
• 英文名称: 4,4'-bis-(2-phthalimido-ethyl)-[2,2']bithiazolyl
• 英文别名: 4,4'-Bis-(2-phthalimido-aethyl)-[2,2']bithiazolyl；2-[2-[2-[4-[2-(1,3-Dioxoisoindol-2-yl)ethyl]-1,3-thiazol-2-yl]-1,3-thiazol-4-yl]ethyl]isoindole-1,3-dione
• 化学式: C₂₆H₁₈N₄O₄S₂
• 分子量: 514.585
• InChiKey: ODBJJEFHZZLDOU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  36
• 可旋转键数：
  7
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.15
• 拓扑面积：
  157
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  4,4'-bis-(2-phthalimido-ethyl)-[2,2']bithiazolyl 在 盐酸 、 溶剂黄146 作用下， 生成 4,4'-bis-(2-amino-ethyl)-[2,2']bithiazolyl; dihydrochloride
  参考文献：
  名称：

  Michalsky; Borkovec, Chemicke Listy, 1954, vol. 48, p. 1260

  摘要：

  DOI：
• 作为产物：
  描述：

  1-重氮基-4-苯基-2-丁酮 在 乙醇 、 水 、 氢溴酸 、 溶剂黄146 作用下， 生成 4,4'-bis-(2-phthalimido-ethyl)-[2,2']bithiazolyl
  参考文献：
  名称：

  Michalsky; Borkovec, Chemicke Listy, 1954, vol. 48, p. 1260

  摘要：

  DOI：

文献信息

• Composition including ADAM9 inhibitor and the use thereof
  申请人：China Medical University

  公开号：US11357759B2

  公开（公告）日：2022-06-14

  The present disclosure relates to an ADAM9 inhibitor compound of formula (I), including salts, hydrates and stereoisomers thereof, compositions thereof, and methods of use therefor, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.

  本公开涉及一种式（I）的ADAM9抑制剂化合物，包括其盐类、水合物和立体异构体，其组合物及其使用方法，包括用有效量的化合物或组合物治疗有需要的人，并检测该人的健康或状况因此得到的改善。
• Composition Including ADAM9 Inhibitor And The Use Thereof
  申请人：China Medical University

  公开号：US20210052562A1

  公开（公告）日：2021-02-25

  The present disclosure relates to an ADAM9 inhibitor compound of formula (I), including salts, hydrates and stereoisomers thereof, compositions thereof, and methods of use therefor, including treating a person in need thereof with an effective amount of the compound or composition, and detecting a resultant improvement in the person's health or condition.
• Use Of ADAM9 Inhibitor As Immunomodulator
  申请人：China Medical University

  公开号：US20220202783A1

  公开（公告）日：2022-06-30

  The present disclosure relates to a use of an ADAM9 inhibitor in manufacture of an immunomodulator. The immunomodulator can change the distribution of immune cells in a tumor and increase the infiltration of the immune cells, thereby increasing the efficacy of cancer immunotherapy. Furthermore, the immunomodulator can be used to enhance an effectiveness of a cancer immunotherapy, and the ADAM9 inhibitor can be a compound of Formula (I), or a pharmaceutically acceptable salt or stereoisomer thereof.